Abstract
Simple SummaryMelitherapy is an innovative therapeutic approach to treat different diseases, including cancer, and it is based on the regulation of cell membrane composition and structure, which modulates relevant signal pathways. In this context, 2-hydroxycervonic acid (HCA) was designed for patients with cancer or other pathologies who have received ineffective and safe treatment. Here, we have tested the effects of HCA on glioblastoma cells and xenograft tumors (mice). HCA appeared to enhance endoplasmic reticulum stress/unfolded protein response signaling, which consequently induced autophagic cell death of the glioblastoma tumor cells. In light of the data obtained, it would clearly be worthwhile to undertake more clinically orientated studies to fully assess the potential of HCA to combat glioblastoma in patients.Glioblastoma (GBM) is the most common and aggressive type of primary brain tumor in adults, and the median survival of patients with GBM is 14.5 months. Melitherapy is an innovative therapeutic approach to treat different diseases, including cancer, and it is based on the regulation of cell membrane composition and structure, which modulates relevant signal pathways. Here, we have tested the effects of 2-hydroxycervonic acid (HCA) on GBM cells and xenograft tumors. HCA was taken up by cells and it compromised the survival of several human GBM cell lines in vitro, as well as the in vivo growth of xenograft tumors (mice) derived from these cells. HCA appeared to enhance ER stress/UPR signaling, which consequently induced autophagic cell death of the GBM tumor cells. This negative effect of HCA on GBM cells may be mediated by the JNK/c-Jun/CHOP/BiP axis, and it also seems to be provoked by the cellular metabolite of HCA, C21:5n-3 (heneicosapentaenoic acid). These results demonstrate the efficacy of the melitherapeutic treatment used and the potential of using C21:5n-3 as an efficacy biomarker for this treatment. Given the safety profile in animal models, the data presented here provide evidence that HCA warrants further clinical study as a potential therapy for GBM, currently an important unmet medical need.
Highlights
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults [1,2]
We have studied the effects of hydroxycervonic acid (HCA) on GBM, showing that this hydroxylderivative of DHA regulates cell signaling and triggers GBM cell death through unfolded protein response (UPR) and autophagy
HCA and DHA provoked a reduction in GBM cell number at all the time points studied (Figure 1B), and the IC50 values for HCA ranged from 175 ± 10.1 μM in U-118 MG after 24 h to 109.3 ± 7.5 μM after 72 h for SF-295 cells, relatively similar to 126.7 ± 4.1 μM after 24 h in SF-295 cells for DHA to 115 ± 5.5 μM after 72 h in U-118 MG cells
Summary
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults [1,2]. Based on its histopathological characteristics, including necrosis and endothelial proliferation, the World Health Organization (WHO) considers GBM a grade IV cancer, the highest grade of brain tumors [3]. The standard treatment for GBM includes surgery, radiotherapy, and alkylating chemotherapy with Temozolomide (TMZ: [4]). At least 50% of patients fail to respond to TMZ due to the over-expression by down-methylated promotor of O6-methylguanyl DNA methyltransferase (MGMT) and/or deficiencies in the DNA repair pathway in GBM cells [5]. GBM has a remarkably poor prognosis, showing a 5-year survival rate of 4–5%, and in clinical trials, a survival rate at 2 years of only 26–33% [2]. There is a clearly a clinical requirement to develop new therapies that better combat GBM
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
